371 related articles for article (PubMed ID: 33630387)
1. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
Imafuku S; Nakagawa H; Igarashi A; Morita A; Okubo Y; Sano S; Tada Y; Nemoto O; Rozzo SJ; Kawamura M; Ohtsuki M
J Dermatol; 2021 Jun; 48(6):844-852. PubMed ID: 33523513
[TBL] [Abstract][Full Text] [Related]
3. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
Reich K; Warren RB; Iversen L; Puig L; Pau-Charles I; Igarashi A; Ohtsuki M; Falqués M; Harmut M; Rozzo S; Lebwohl MG; Cantrell W; Blauvelt A; Thaçi D
Br J Dermatol; 2020 Mar; 182(3):605-617. PubMed ID: 31218661
[TBL] [Abstract][Full Text] [Related]
5. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
[TBL] [Abstract][Full Text] [Related]
6. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
Thaci D; Piaserico S; Warren RB; Gupta AK; Cantrell W; Draelos Z; Foley P; Igarashi A; Langley RG; Asahina A; Young M; Falqués M; Pau-Charles I; Mendelsohn AM; Rozzo SJ; Reich K
Br J Dermatol; 2021 Aug; 185(2):323-334. PubMed ID: 33544883
[TBL] [Abstract][Full Text] [Related]
7. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.
Blauvelt A; Sofen H; Papp K; Gooderham M; Tyring S; Zhao Y; Lowry S; Mendelsohn A; Parno J; Reich K
J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2305-2312. PubMed ID: 31407394
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.
Kimball AB; Papp KA; Reich K; Gooderham M; Li Q; Cichanowitz N; La Rosa C; Blauvelt A
Br J Dermatol; 2020 Jun; 182(6):1359-1368. PubMed ID: 31487406
[TBL] [Abstract][Full Text] [Related]
9. Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
Lebwohl MG; Leonardi CL; Mehta NN; Gottlieb AB; Mendelsohn AM; Parno J; Rozzo SJ; Menter MA
J Am Acad Dermatol; 2021 Feb; 84(2):398-407. PubMed ID: 32961255
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis.
Poulin Y; Ramon M; Rosoph L; Weisman J; Mendelsohn AM; Parno J; Rozzo SJ; Lee P
J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1500-1509. PubMed ID: 31919889
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
Blauvelt A; Kimball AB; Augustin M; Okubo Y; Witte MM; Capriles CR; Sontag A; Arora V; Osuntokun O; Strober B
Br J Dermatol; 2022 Dec; 187(6):866-877. PubMed ID: 35791755
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
Papp KA; Reich K; Blauvelt A; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaci D; Li Q; Cichanowitz N; Green S; La Rosa C
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1098-1106. PubMed ID: 30838709
[TBL] [Abstract][Full Text] [Related]
14. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
Elewski B; Menter A; Crowley J; Tyring S; Zhao Y; Lowry S; Rozzo S; Mendelsohn AM; Parno J; Gordon K
J Dermatolog Treat; 2020 Dec; 31(8):763-768. PubMed ID: 31268369
[No Abstract] [Full Text] [Related]
15. Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
Fernandez AP; Dauden E; Gerdes S; Lebwohl MG; Menter MA; Leonardi CL; Gooderham M; Gebauer K; Tada Y; Lacour JP; Bianchi L; Egeberg A; Pau-Charles I; Mendelsohn AM; Rozzo SJ; Mehta NN
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1774-1783. PubMed ID: 35460287
[TBL] [Abstract][Full Text] [Related]
16. Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial.
Warren RB; Carrascosa JM; Fumero E; Schoenenberger A; Lebwohl MG; Szepietowski JC; Reich K
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):919-927. PubMed ID: 32979235
[TBL] [Abstract][Full Text] [Related]
17. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
18. Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension.
Yu C; Geng S; Yang B; Deng Y; Li F; Kang X; Bi M; Zhang F; Zhao Y; Pan W; Tian Z; Xu J; Zhang Z; Yu N; Duan X; Guo S; Sun Q; Li W; Tao J; Liu Z; Yin Y; Wang G
Chin Med J (Engl); 2024 May; 137(10):1190-1198. PubMed ID: 38192233
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
20. Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis.
Frampton JE
Am J Clin Dermatol; 2019 Apr; 20(2):295-306. PubMed ID: 30924030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
